Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl ester as ATP-competitive inhibitors of BRAF: A bioinformatics study

Ascierto, 2012, The role of BRAF V600 mutation in melanoma, J. Transl. Med., 10, 85, 10.1186/1479-5876-10-85 Avruch, 2001, Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade, Recent Prog. Horm. Res., 56, 127, 10.1210/rp.56.1.127 Ballantyne, 2013, Dabrafenib: first global approval, Drugs, 73, 1367, 10.1007/s40265-013-0095-2 Choromanska, 2020, Caffeic acid phenethyl ester assisted by reversible electroporation-in vitro study on human melanoma cells, Pharmaceutics, 12, 10.3390/pharmaceutics12050478 Cohen, 2012, A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers, Am. J. Surg., 204, 895, 10.1016/j.amjsurg.2012.07.027 Cotto-Rios, 2020, Inhibitors of BRAF dimers using an allosteric site, Nat. Commun., 11, 4370, 10.1038/s41467-020-18123-2 Crispo, 2019, BRAF inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives, Cancers, 11, 10.3390/cancers11091388 Croce, 2019, The multifaceted anti-cancer effects of BRAF-inhibitors, Oncotarget, 10, 6623, 10.18632/oncotarget.27304 Delord, 2017, Phase I dose-escalation and -expansion study of the BRAF inhibitor Encorafenib (LGX818) in metastatic BRAF-mutant melanoma, Clin. Cancer Res. : J. Am. Assoc. Cancer Res., 23, 5339, 10.1158/1078-0432.CCR-16-2923 Desai, 2020, Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors, J. Clin. Oncol. : J. Am. Soc. Clin. Oncol., 38, 2140, 10.1200/JCO.19.02654 Dhanjal, 2021, Molecular mechanism of anti-SARS-CoV2 activity of Ashwagandha-derived withanolides, Int. J. Biol. Macromol., 184, 297, 10.1016/j.ijbiomac.2021.06.015 Diukendjieva, 2020, Dual SMO/BRAF inhibition by flavonolignans from Silybum marianum (dagger), Antioxidants, 9, 10.3390/antiox9050384 Dutta, 2019, Withania somnifera (ashwagandha) and withaferin A: potential in integrative oncology, Int. J. Mol. Sci., 20, 10.3390/ijms20215310 Fofaria, 2017, Therapeutic potential of black pepper compound for BRaf resistant melanoma, Proceedings, 1, 981, 10.3390/proceedings1100981 Friesner, 2006, Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein− ligand complexes, J. Med. Chem., 49, 6177, 10.1021/jm051256o Gao, 2014, Withanone-rich combination of Ashwagandha withanolides restricts metastasis and angiogenesis through hnRNP-K, Mol. Cancer Therapeut., 13, 2930, 10.1158/1535-7163.MCT-14-0324 Genheden, 2015, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expet Opin. Drug Discov., 10, 449, 10.1517/17460441.2015.1032936 Gentilcore, 2013, Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations, BMC Cancer, 13, 17, 10.1186/1471-2407-13-17 Grasso, 2016, Chemically linked Vemurafenib inhibitors promote an inactive BRAF(V600E) conformation, ACS Chem. Biol., 11, 2876, 10.1021/acschembio.6b00529 Guvench, 2008, Comparison of protein force fields for molecular dynamics simulations, Methods Mol. Biol., 443, 63, 10.1007/978-1-59745-177-2_4 Haling, 2014, Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling, Cancer Cell, 26, 402, 10.1016/j.ccr.2014.07.007 Holderfield, 2014, Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond, Nat. Rev. Cancer, 14, 455, 10.1038/nrc3760 Hu, 2015, Kinase regulation by hydrophobic spine assembly in cancer, Mol. Cell Biol., 35, 264, 10.1128/MCB.00943-14 Huang, 2021, Natural products in cancer therapy: past, present and future, Nat. Prod. Bioprospecting, 11, 5, 10.1007/s13659-020-00293-7 Humphrey, 1996, VMD - visual molecular dynamics, J. Mol. Graph., 14, 33, 10.1016/0263-7855(96)00018-5 Ichikawa, 2006, Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression, Mol. Cancer Therapeut., 5, 1434, 10.1158/1535-7163.MCT-06-0096 Karoulia, 2017, New perspectives for targeting RAF kinase in human cancer, Nat. Rev. Cancer, 17, 676, 10.1038/nrc.2017.79 King, 2013, Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions, PLoS One, 8, 10.1371/journal.pone.0067583 Kumar, 2021, Possible link between higher transmissibility of alpha, Kappa and delta variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity, Int. J. Mol. Sci., 22 Kunimasa, 2017, Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters, Cancer Sci., 108, 1368, 10.1111/cas.13266 Malik, 2020 Malik, 2021, Computational insights into the potential of withaferin-A, Withanone and caffeic acid phenethyl ester for treatment of aberrant-EGFR driven lung cancers, Biomolecules, 11, 160, 10.3390/biom11020160 Mulakala, 2013, Could MM-GBSA be accurate enough for calculation of absolute protein/ligand binding free energies?, J. Mol. Graph. Model., 46, 41, 10.1016/j.jmgm.2013.09.005 Muller, 2017, Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel, Crit. Rev. Oncol.-Hematol., 120, 52, 10.1016/j.critrevonc.2017.10.002 Munoz-Couselo, 2015, Recent advances in the treatment of melanoma with BRAF and MEK inhibitors, Ann. Transl. Med., 3, 207 Newman, 2016, Natural products as sources of new drugs from 1981 to 2014, J. Nat. Prod., 79, 629, 10.1021/acs.jnatprod.5b01055 Newman, 2020, Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019, J. Nat. Prod., 83, 770, 10.1021/acs.jnatprod.9b01285 Nishikawa, 2015, Withaferin A induces cell death selectively in androgen-independent prostate cancer cells but not in normal fibroblast cells, PLoS One, 10, 10.1371/journal.pone.0134137 Ozturk, 2012, The anticancer mechanism of caffeic acid phenethyl ester (CAPE): review of melanomas, lung and prostate cancers, Eur. Rev. Med. Pharmacol. Sci., 16, 2064 Proietti, 2020, BRAF inhibitors: molecular targeting and immunomodulatory actions, Cancers, 12, 10.3390/cancers12071823 2018 Roos, 2019, OPLS3e: extending Force Field Coverage for Drug-Like Small Molecules, J. Chem. Theor. Comput., 15, 1863, 10.1021/acs.jctc.8b01026 Sanchez, 2018, BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers, Drugs, 78, 549, 10.1007/s40265-018-0884-8 Sari, 2020, Combination of withaferin-A and CAPE provides superior anticancer potency: bioinformatics and experimental evidence to their molecular targets and mechanism of action, Cancers, 12, 10.3390/cancers12051160 Savoia, 2019, Targeting the ERK signaling pathway in melanoma, Int. J. Mol. Sci., 20, 10.3390/ijms20061483 Shirley, 2018, Encorafenib and binimetinib: first global approvals, Drugs, 78, 1277, 10.1007/s40265-018-0963-x Siddharth, 2019, Concomitant inhibition of cytoprotective autophagy augments the efficacy of withaferin A in hepatocellular carcinoma, Cancers, 11, 10.3390/cancers11040453 Tan, 2019, Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies, OncoTargets Ther., 12, 635, 10.2147/OTT.S189391 Tang, 2015, BGB-283, a novel RAF kinase and EGFR inhibitor, displays potent antitumor activity in BRAF-mutated colorectal cancers, Mol. Cancer Therapeut., 14, 2187, 10.1158/1535-7163.MCT-15-0262 Vangone, 2015, Contacts-based prediction of binding affinity in protein-protein complexes, eLife, 4, 10.7554/eLife.07454 Villanueva, 2011, Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options, Cancer Res., 71, 7137, 10.1158/0008-5472.CAN-11-1243 Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/S0092-8674(04)00215-6 Wang, 2021, Effect of the force field on molecular dynamics simulations of the multidrug efflux protein P-glycoprotein, J. Chem. Theor. Comput., 17, 6491, 10.1021/acs.jctc.1c00414 Widodo, 2010, Selective killing of cancer cells by Ashwagandha leaf extract and its component Withanone involves ROS signaling, PLoS One, 5, 10.1371/journal.pone.0013536 Wu, 2011, Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer, Cancer Lett., 308, 43, 10.1016/j.canlet.2011.04.012 Xue, 2016, PRODIGY: a web server for predicting the binding affinity of protein-protein complexes, Bioinformatics, 32, 3676, 10.1093/bioinformatics/btw514 Yadav, 2017, Molecular docking, QSAR and ADMET studies of withanolide analogs against breast cancer, Drug Des. Dev. Ther., 11, 1859, 10.2147/DDDT.S130601 Yu, 2017, Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences, Cell Death Dis., 8, 10.1038/cddis.2017.33